fda warning letters glp-1 compounders september 2025 news 🚨 Moves to Shut Down Mass-Market Compounded GLP-1s The FDA is taking action to restrict widely marketed, non–FDA-approved compounded products, citing concerns over safety, quality, and misleading claims. As demand National Hispanic Medical Association |

Editorial Advisory Board Member, Harvard Health Publishing The GLP-1 drugs, which include semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound), are turning out to have effects that go beyond shedding pounds and controlling diabetes

Physiotherapy can also help to maintain and improve muscle strength, flexibility, balance, coordination, and endurance

The authors also note that the patient did not initially disclose his alcohol use because of guilt and stigma, highlighting the need for stronger AUD screening and diagnostic efforts within family medicine clinics

Avoid starting new patients on GLP-1 treatment until supply stabilizes

Supports even skin tone and reduces pigmentation

Their labels contain drug claims stating the products can diagnose, cure, mitigate, treat, or prevent disease